Francisco J. Hernandez-Ilzaliturri

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

M. Berger, A. Goy, B. Kahl, 2014, Leukemia & lymphoma.

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

M. Berger, A. Goy, B. Kahl, 2014, Leukemia & lymphoma.